JP6860575B2 - 神経変性障害の処置に用いられるホメオタンパク質 - Google Patents

神経変性障害の処置に用いられるホメオタンパク質 Download PDF

Info

Publication number
JP6860575B2
JP6860575B2 JP2018534025A JP2018534025A JP6860575B2 JP 6860575 B2 JP6860575 B2 JP 6860575B2 JP 2018534025 A JP2018534025 A JP 2018534025A JP 2018534025 A JP2018534025 A JP 2018534025A JP 6860575 B2 JP6860575 B2 JP 6860575B2
Authority
JP
Japan
Prior art keywords
neurons
mice
ohda
disease
snpc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018534025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536697A (ja
JP2018536697A5 (https=
Inventor
プロシアンツ、アラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2018536697A publication Critical patent/JP2018536697A/ja
Publication of JP2018536697A5 publication Critical patent/JP2018536697A5/ja
Application granted granted Critical
Publication of JP6860575B2 publication Critical patent/JP6860575B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2018534025A 2015-09-23 2016-09-23 神経変性障害の処置に用いられるホメオタンパク質 Active JP6860575B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306482.9 2015-09-23
EP15306482 2015-09-23
PCT/EP2016/072675 WO2017071889A1 (en) 2015-09-23 2016-09-23 Homeoproteins for use in the treatment of neurodegenerative disorders

Publications (3)

Publication Number Publication Date
JP2018536697A JP2018536697A (ja) 2018-12-13
JP2018536697A5 JP2018536697A5 (https=) 2019-09-05
JP6860575B2 true JP6860575B2 (ja) 2021-04-14

Family

ID=54207439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018534025A Active JP6860575B2 (ja) 2015-09-23 2016-09-23 神経変性障害の処置に用いられるホメオタンパク質

Country Status (7)

Country Link
US (2) US20190247461A1 (https=)
EP (2) EP3352777B1 (https=)
JP (1) JP6860575B2 (https=)
CN (1) CN108289929A (https=)
ES (2) ES2895154T3 (https=)
PL (2) PL3960195T3 (https=)
WO (1) WO2017071889A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120676931A (zh) 2023-01-13 2025-09-19 布瑞恩维公司 Engrailed蛋白的稳定水性组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662698A1 (fr) 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
FR2897780B1 (fr) 2006-02-28 2008-05-23 Centre Nat Rech Scient Utilisation de la proteine a homeodomaine engrailed comme anxiolytique
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
FR2926023B1 (fr) 2008-01-09 2010-02-26 Centre Nat Rech Scient Utilisation d'une homoproteine de la famille bicoid pour le traitement du glaucome.
RU2012100903A (ru) * 2009-07-13 2013-08-20 Зе Юниверсити Оф Саррей Терапевтические пептиды, полипептиды и последовательности нуклеиновых кислот
WO2013128239A1 (en) * 2012-02-29 2013-09-06 Centre National De La Recherche Scientifique Use of engrailed for increasing dopamine synthesis by dopaminergic neurons

Also Published As

Publication number Publication date
EP3960195B1 (en) 2025-01-08
JP2018536697A (ja) 2018-12-13
PL3352777T3 (pl) 2022-02-07
EP3352777A1 (en) 2018-08-01
EP3960195A1 (en) 2022-03-02
WO2017071889A1 (en) 2017-05-04
CA2999209A1 (en) 2017-05-04
CN108289929A (zh) 2018-07-17
US20210379144A1 (en) 2021-12-09
ES3010130T3 (en) 2025-04-01
US20190247461A1 (en) 2019-08-15
PL3960195T3 (pl) 2025-06-09
ES2895154T3 (es) 2022-02-17
EP3352777B1 (en) 2021-09-15

Similar Documents

Publication Publication Date Title
Bertrand et al. Application of Rho antagonist to neuronal cell bodies promotes neurite growth in compartmented cultures and regeneration of retinal ganglion cell axons in the optic nerve of adult rats
Shah et al. Voltage-gated potassium channels at the crossroads of neuronal function, ischemic tolerance, and neurodegeneration
Carty et al. SARM: From immune regulator to cell executioner
Batulan et al. Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis
JP5643237B2 (ja) 光受容細胞のアポトーシスを抑制する方法
Qiu et al. AAV8-mediated angiotensin-converting enzyme 2 gene delivery prevents experimental autoimmune uveitis by regulating MAPK, NF-κB and STAT3 pathways
Wu et al. Recombinant adiponectin peptide promotes neuronal survival after intracerebral haemorrhage by suppressing mitochondrial and ATF4‐CHOP apoptosis pathways in diabetic mice via Smad3 signalling inhibition
CA3035675C (en) Pharmaceutical composition containing mtor inhibitor for treating macular degeneration
Akaiwa et al. Topical ripasudil suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma
Gu et al. Piperlongumine attenuates experimental autoimmune encephalomyelitis through inhibition of NF-kappaB activity
KR20190120197A (ko) 치료 및 신경보호 펩티드
US20130197069A1 (en) Methods for treating stress induced emotional disorders
Kojima et al. Axonal protection by modulation of p62 expression in TNF-induced optic nerve degeneration
JP6860575B2 (ja) 神経変性障害の処置に用いられるホメオタンパク質
US7749496B2 (en) Neuronal regeneration
WO2019134574A1 (zh) 防治端粒功能异常相关疾病的多肽及医药用途
CN115475247A (zh) β2-微球蛋白或其抑制剂的制药用途
JP7630540B2 (ja) 神経保護ペプチド
CA2999209C (en) Homeoproteins for use in the treatment of neurodegenerative disorders
US8329643B2 (en) PIMAP39 modulates LPS-induced inflammatory response
CA3204205A1 (en) Lectin protein for treatment and prevention of neurodegenerative diseases
US20120225821A1 (en) Composition for preventing or treating a spinal cord injury
WO2023279067A1 (en) Targeting piezo1 to treat inherited and age-related macular degenerations
Kanazawa Therapeutic strategies in Huntington’s disease
Li et al. Defensins: Key Molecules in Ocular Surface Protection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210326

R150 Certificate of patent or registration of utility model

Ref document number: 6860575

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250